The FDA has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for use in combination with androgen receptor pathway inhibitors in adults with PSMA-positive metastatic prostate cancer.

ClinicalJuly 17, 2026

Novartis initiates real-world study on Pluvicto in metastatic CRPC patients

Novartis is conducting a real-world study to evaluate the effectiveness of Pluvicto in metastatic CRPC patients.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Novartis — Pluvicto

July 17, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Oncology →

Oncology · Radioligand Therapy →

Radioligand Therapy →

Radiopharmaceutical →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.